Literature DB >> 2208797

Plasma and tissue interleukin-2 receptor levels in inflammatory bowel disease.

Y R Mahida1, A Gallagher, L Kurlak, C J Hawkey.   

Abstract

Plasma and tissue interleukin-2 receptor (IL-2R) levels were determined in patients with active ulcerative colitis and Crohn's disease. Compared with healthy controls (median 440 U/ml; range 240-900), significantly higher levels of plasma IL-2R were present in patients with active ulcerative colitis (median 1180 U/ml; range 580-7150; P less than 0.002) and Crohn's disease (median 1340 U/ml; range 480-9000; P less than 0.002). Compared with other laboratory parameters, plasma IL-2R levels were related most closely to clinical score of disease activity in Crohn's disease. Plasma IL-2R levels also reflected the clinical course and may provide a more accurate assessment of disease activity in Crohn's disease. In plasma of patients undergoing intestinal resection of active inflammatory bowel disease, raised levels of IL-2R were present in samples from mesenteric vein (draining inflamed intestine) compared with those from peripheral vein. In tissue homogenates of colonic biopsies, significantly higher levels of IL-2R were present in specimens from colons with active ulcerative colitis compared with healthy controls (median 230.2, range 20.7-581.5 versus 77.9, range 34.2-291.3; P less than 0.02).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2208797      PMCID: PMC1535179          DOI: 10.1111/j.1365-2249.1990.tb05406.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  15 in total

1.  Interleukin-2 receptor proteins.

Authors:  I Trowbridge
Journal:  Nature       Date:  1987 Jun 11-17       Impact factor: 49.962

2.  Activation of peripheral blood and intestinal lamina propria lymphocytes in Crohn's disease. In vivo state of activation and in vitro response to stimulation as defined by the expression of early activation antigens.

Authors:  F Pallone; S Fais; O Squarcia; L Biancone; P Pozzilli; M Boirivant
Journal:  Gut       Date:  1987-06       Impact factor: 23.059

3.  A simple index of Crohn's-disease activity.

Authors:  R F Harvey; J M Bradshaw
Journal:  Lancet       Date:  1980-03-08       Impact factor: 79.321

4.  Involvement of the immune system in the pathogenesis of Crohn's disease. Expression of the T9 antigen on peripheral immunocytes correlates with the severity of the disease.

Authors:  A Raedler; S Fraenkel; G Klose; K Seyfarth; H G Thiele
Journal:  Gastroenterology       Date:  1985-04       Impact factor: 22.682

5.  C reactive protein concentrations in neonates: determination by a latex enhanced immunoassay.

Authors:  C O'Callaghan; P Franklin; T S Elliott; I Deverill; N Richards; R J Powell
Journal:  J Clin Pathol       Date:  1984-09       Impact factor: 3.411

6.  Interleukin 2 receptor expression by macrophages in inflammatory bowel disease.

Authors:  Y R Mahida; S Patel; K Wu; D P Jewell
Journal:  Clin Exp Immunol       Date:  1988-12       Impact factor: 4.330

7.  T-cell abnormalities in inflammatory bowel disease are mediated by interleukin 2.

Authors:  E C Ebert; S H Wright; W H Lipshutz; S P Hauptman
Journal:  Clin Immunol Immunopathol       Date:  1984-11

8.  A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis.

Authors:  J Powell-Tuck; R L Bown; J E Lennard-Jones
Journal:  Scand J Gastroenterol       Date:  1978       Impact factor: 2.423

9.  Interleukin 2 activity of human intestinal mucosa mononuclear cells. Decreased levels in inflammatory bowel disease.

Authors:  C Fiocchi; M L Hilfiker; K R Youngman; N C Doerder; J H Finke
Journal:  Gastroenterology       Date:  1984-04       Impact factor: 22.682

10.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

Authors:  L A Rubin; C C Kurman; M E Fritz; W E Biddison; B Boutin; R Yarchoan; D L Nelson
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

View more
  20 in total

1.  Inflammatory bowel disease: definition, epidemiology, etiologic aspects, and immunogenetic studies.

Authors:  Bing Xia; JBA Crusius; SGM Meuwissen; AS Pe?a
Journal:  World J Gastroenterol       Date:  1998-10       Impact factor: 5.742

2.  In vitro production of TNF-alpha,IL-6 and sIL-2R in Chinese patients with ulcerative colitis.

Authors:  Bing Xia; Hai-Jian Guo; JBA Crusius; Chang-Sheng Deng; SGM Meuwissen; AS Pena
Journal:  World J Gastroenterol       Date:  1998-06       Impact factor: 5.742

Review 3.  Potential role of superantigen induced activation of cell mediated immune mechanisms in the pathogenesis of Crohn's disease.

Authors:  J P Ibbotson; J R Lowes
Journal:  Gut       Date:  1995-01       Impact factor: 23.059

4.  Soluble interleukin-2 receptor in Crohn's disease. Assessment of disease activity and prediction of relapse.

Authors:  E Louis; J Belaiche; C Van Kemseke; N Schaaf; P Mahieu; J Y Mary
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

Review 5.  Immunopathology of human inflammatory bowel disease.

Authors:  P Brandtzaeg; G Haraldsen; J Rugtveit
Journal:  Springer Semin Immunopathol       Date:  1997

6.  Common variable immunodeficiency with CD4+ T lymphocytopenia and overproduction of soluble IL-2 receptor associated with Turner's syndrome and dorsal kyphoscoliosis.

Authors:  R A al-Attas; A H Rahi
Journal:  J Clin Pathol       Date:  1997-10       Impact factor: 3.411

7.  Molecular mechanism of interleukin-2-induced mucosal homeostasis.

Authors:  Jayshree Mishra; Christopher M Waters; Narendra Kumar
Journal:  Am J Physiol Cell Physiol       Date:  2011-11-23       Impact factor: 4.249

Review 8.  Lymphocyte and macrophage interleukin receptors in inflammatory bowel disease: a more selective target for therapy?

Authors:  M J Weldon; J D Maxwell
Journal:  Gut       Date:  1994-07       Impact factor: 23.059

9.  Adequacy of mucosal biopsies for evaluation of intestinal cytokine-specific mRNA. Comparative study of RT-PCR in biopsies and isolated cells from normal and inflamed intestine.

Authors:  K Fukushima; G West; C Fiocchi
Journal:  Dig Dis Sci       Date:  1995-07       Impact factor: 3.199

10.  Increased in vitro release of soluble interleukin 2 receptor by colonic lamina propria mononuclear cells in inflammatory bowel disease.

Authors:  S Schreiber; A Raedler; A R Conn; J L Rombeau; R P MacDermott
Journal:  Gut       Date:  1992-02       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.